Dicyclomine: Difference between revisions
No edit summary |
(Add See Also section) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 3: | Line 3: | ||
*Indication: FDA approved for irritable bowel syndrome. Used off-label for cramping associated with opioid withdrawal | *Indication: FDA approved for irritable bowel syndrome. Used off-label for cramping associated with opioid withdrawal | ||
*Dosage Forms: PO, IM | *Dosage Forms: PO, IM | ||
**DO NOT GIVE IV | **'''DO NOT GIVE IV''' | ||
*Common Trade Names: Bentyl | *Common Trade Names: Bentyl | ||
| Line 49: | Line 49: | ||
*Excretion: Urine ~80%, ~10% feces | *Excretion: Urine ~80%, ~10% feces | ||
*Mechanism of Action: antimuscarinic, direct smooth muscle antagonism of bradykinin and histamine-induced muscular spasms, which [[atropine]] does not | *Mechanism of Action: antimuscarinic, direct smooth muscle antagonism of bradykinin and histamine-induced muscular spasms, which [[atropine]] does not | ||
==See Also== | |||
*[[Irritable bowel syndrome]] | |||
*[[Anticholinergics]] | |||
*[[Abdominal pain]] | |||
==References== | ==References== | ||
Latest revision as of 09:10, 22 March 2026
General
- Type: antispasmodic, anticholinergics (antimuscarinic)
- Indication: FDA approved for irritable bowel syndrome. Used off-label for cramping associated with opioid withdrawal
- Dosage Forms: PO, IM
- DO NOT GIVE IV
- Common Trade Names: Bentyl
Adult Dosing
- 10-20 mg PO or IM q6 PRN
Pediatric Dosing
Safety/efficacy not established
Contraindications
- Allergy to class/drug
- Age <6 mo
- Breastfeeding
- GI obstruction
- Obstructive uropathy
- Reflux esophagitis
- Severe ulcerative colitis
- Myasthenia gravis
- Glaucoma
- Unstable hemodynamics
Adverse Reactions
Serious
- See Anticholinergic toxicity
- Syncope, poor muscle tone
- Dyspnea, apnea, respiratory arrest
- Anaphylaxis, angioedema
- Seizure, coma
- Impaired sweating/thermoregulation
- Paralytic ileus, intestinal perforation, pseudo-obstruction, toxic megacolon
- Psychosis
Common
- Nausea, xerostomia
- Asthenia, dizziness, somnolence, nervousness
- Blurred vision
Special Populations
- Pregnancy Rating: B
- Lactation: Infant risk has been demonstrated
- Renal Dosing: not defined
- Hepatic Dosing: not defined
Pharmacology
- Half-life: ~2 hours
- Excretion: Urine ~80%, ~10% feces
- Mechanism of Action: antimuscarinic, direct smooth muscle antagonism of bradykinin and histamine-induced muscular spasms, which atropine does not